カテゴリ： GlobalData, アメリカ, 企業調査

Foundation Medicine Inc (FMI)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Foundation Medicine Inc (FMI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014170
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：60
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Foundation Medicine Inc (Foundation Medicine), a subsidiary of F. Hoffmann-La Roche Ltd is a healthcare products provider that offers cancer care solutions. The company offers molecular information and cancer research programs. It offers clinical products which include FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas and others. It also offers additional materials, services, and real-time data through its technology products. The company partners with biotech and pharmaceutical companies to develop targeted cancer therapies and active clinical trials. Foundation Medicine is headquartered in Cambridge, Massachusetts, the US.

Foundation Medicine Inc (FMI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 16
Partnerships 17
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 17
Epizyme Enters into Agreement with Foundation Medicine 18
Foundation Medicine Enters into Agreement with AstraZeneca 19
Foundation Medicine Partners with AstraZeneca 20
Foundation Medicine Enters into Agreement with Mirati Therapeutics 21
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 22
Roche Amends R&D Agreement with Foundation Medicine 23
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 24
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 25
Foundation Medicine Expands Co-Development Agreement With Novartis 26
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 27
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 28
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 29
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30
Equity Offering 31
Foundation Medicine Raises USD250 Million in Private Placement of Shares 31
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 32
Foundation Medicine Completes IPO Of Shares For US$122 Million 33
Acquisition 34
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 34
Foundation Medicine Inc – Key Competitors 36
Foundation Medicine Inc – Key Employees 37
Foundation Medicine Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Nov 01, 2017: Foundation Medicine Announces 2017 Third Quarter Results and Recent Highlights 39
Aug 01, 2017: Foundation Medicine Announces 2017 Second Quarter Results and Recent Highlights 40
May 09, 2017: Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights 42
Feb 22, 2017: Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook 44
Jan 09, 2017: Foundation Medicine Reports Preliminary 2016 Results 45
Nov 02, 2016: Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights 47
Aug 02, 2016: Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights 49
May 03, 2016: Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights 51
Feb 23, 2016: Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook 52
Jan 11, 2016: Foundation Medicine Reports Preliminary 2015 Results and Provides 2016 Business Outlook, including Commercial Launch of its ctDNA Assay 53
Corporate Communications 54
Oct 10, 2017: Foundation Medicine Appoints Tom Civik as Chief Commercial Officer 54
Jan 06, 2017: Foundation Medicine Announces Executive Leadership Transition 55
Oct 27, 2016: Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors 56
Product News 57
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 57
Other Significant Developments 59
Feb 25, 2016: Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 16
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 17
Epizyme Enters into Agreement with Foundation Medicine 18
Foundation Medicine Enters into Agreement with AstraZeneca 19
Foundation Medicine Partners with AstraZeneca 20
Foundation Medicine Enters into Agreement with Mirati Therapeutics 21
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 22
Roche Amends R&D Agreement with Foundation Medicine 23
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 24
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 25
Foundation Medicine Expands Co-Development Agreement With Novartis 26
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 27
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 28
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 29
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30
Foundation Medicine Raises USD250 Million in Private Placement of Shares 31
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 32
Foundation Medicine Completes IPO Of Shares For US$122 Million 33
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 34
Foundation Medicine Inc, Key Competitors 36
Foundation Medicine Inc, Key Employees 37
Foundation Medicine Inc, Other Locations 38

★海外企業調査レポート[Foundation Medicine Inc (FMI)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Re-Vana Therapeutics Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Re-Vana Therapeutics Ltd (Re-Vana) is an ocular pharmaceutical and drug delivery company that develops and commercialization of biodegradable long- acting drug delivery platforms to treat ophthalmic conditions. The company provides drug delivery products such as OcuLief, an injectable platfo …
  • G M Breweries Ltd：企業の戦略・SWOT・財務情報
    G M Breweries Ltd - Strategy, SWOT and Corporate Finance Report Summary G M Breweries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Yung Shin Pharma Ind Co Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Yung Shin Pharma Ind Co Ltd (Yung Shin Pharma), a subsidiary of YungShin Global Holding Corporation is a distributor of veterinary drugs, diagnostic kits and active pharmaceutical drugs. The company’s products include carlipin, glix, macgel, diabetin, domper, kascoal, biotase, bisacodyl and …
  • Perpetual Energy Inc (PMT)：石油・ガス：M&Aディール及び事業提携情報
    Summary Perpetual Energy Inc (Perpetual Energy) is an upstream oil and gas company. It explores, develops and produces from shallow gas, liquids-rich gas, heavy oil, bitumen and other assets. The company produces light and medium crude oil, heavy oil natural gas and natural gas liquids. Perpetual En …
  • Livescribe Inc：企業の戦略的SWOT分析
    Livescribe Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Advanced Proteome Therapeutics Corp (APC)-製薬・医療分野：企業M&A・提携分析
    Summary Advanced Proteome Therapeutics Corporation (APC) is a biopharmaceutical company that focuses on the development of anticancer therapeutics that capitalizes on the properties of a natural human protein. It creates, develops and commercializes novel therapies. The company is advancing a site-s …
  • Electricite de France SA：企業の戦略・SWOT・財務情報
    Electricite de France SA - Strategy, SWOT and Corporate Finance Report Summary Electricite de France SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Lookers Plc：企業のM&A・事業提携・投資動向
    Lookers Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lookers Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Brookfield Office Properties Inc：企業のM&A・事業提携・投資動向
    Brookfield Office Properties Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Brookfield Office Properties Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Adani Enterprises Ltd (ADANIENT)：企業の財務・戦略的SWOT分析
    Adani Enterprises Ltd (ADANIENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • STATS UK Ltd：企業の戦略的SWOT分析
    STATS UK Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Mitsui E&S Holdings Co., Ltd. (7003)：石油・ガス：M&Aディール及び事業提携情報
    Summary Mitsui E&S Holdings Co., Ltd. (Mitsui E&S) is a shipbuilding and engineering product manufacturing company. It has diversified business operations comprising environment recycling, construction of social infrastructure, advanced machinery systems, IT-related activities, ships and oceans, pla …
  • Singapore Petroleum Co Ltd：企業の戦略的SWOT分析
    Singapore Petroleum Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Celsius Holdings, Inc.：企業の戦略・SWOT・財務情報
    Celsius Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Celsius Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • MicroPort Scientific Corp (853)：企業の製品パイプライン分析2018
    Summary MicroPort Scientific Corp (MicroPort) a subsidiary of Otsuka Medical Devices Co Ltd is a medical device company which develops, manufactures and markets cardiovascular treatment devices. The company provides products such as cardiovascular devices, orthopedic devices, endovascular devices, e …
  • Sunstone Hotel Investors Inc：戦略・SWOT・企業財務分析
    Sunstone Hotel Investors Inc - Strategy, SWOT and Corporate Finance Report Summary Sunstone Hotel Investors Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Kumagai Gumi Co Ltd (1861)：企業の財務・戦略的SWOT分析
    Kumagai Gumi Co Ltd (1861) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Enea SA (ENA)：企業の財務・戦略的SWOT分析
    Enea SA (ENA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Planet Gas Ltd (PGS)：企業の財務・戦略的SWOT分析
    Summary Planet Gas Ltd (Planet Gas) is an upstream oil and gas company that offers acquisition, exploration, production and development of oil and gas properties in the US. The company holds interests in conventional and unconventional oil and gas projects in Australia. It projects explores for coal …
  • Marubeni Corporation (8002)-エネルギー分野：企業M&A・提携分析
    Summary Marubeni Corporation (Marubeni) is an integrated trading and investment business that operates through its domestic and overseas subsidiaries. It provides various products and commodities such as agri and marine products, chemicals, energy, metals and minerals, machinery, textiles, forest pr …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆